

**TRISALUS LIFE SCIENCES, INC.**

**CHARTER OF THE SCIENCE & TECHNOLOGY COMMITTEE  
OF THE BOARD OF DIRECTORS**

---

**PURPOSE**

The Science & Technology Committee (the “*Committee*”) is established as a committee of the Board of Directors (the “*Board*”) of TriSalus Life Sciences, Inc. (the “*Company*”) with the purpose of periodically reviewing and advising the Board on the Committee’s view of the Company’s scientific strategic direction, including research and development (“*R&D*”) goals and objectives and the implementation thereof. The Committee is also responsible for identifying and discussing significant emerging trends and issues in science and technology and considering their potential impact on the Company.

**COMPOSITION**

The Committee shall consist of at least two (2) members of the Board. Each member shall, in the judgment of the Board, have scientific, medical, clinical or other expertise relevant to biopharmaceutical R&D and the clinical development of product candidates. The members of the Committee shall be appointed by and serve at the discretion of the Board, based on the recommendations of the Nominating & Corporate Governance Committee. Any vacancies occurring on the Committee shall be filled by the Board.

Other members of the Board who are not members of the Committee, members of management and external advisers may be invited to act in an advisory role and/or attend all or part of any meeting, as and when appropriate in the discretion of the Committee’s chairperson or, if none, a majority of Committee members.

**AUTHORITY**

The Committee will have access to all Company books, records, facilities and personnel as deemed necessary or appropriate by any member of the Committee. If the Committee concludes that it must retain legal, accounting or other outside advisors, it may do so and determine compensation terms for those advisors at the Company’s expense. The Committee may also pay any ordinary administrative expenses it deems appropriate in carrying out its duties at the expense of the Company. The Committee will have authority to require that any of the Company’s personnel or outside advisors attend any meeting of the Committee or meet with any member of the Committee or any of its advisors.

The Committee’s chairperson, if one is specified, shall be designated by the Board. The chairperson of the Committee will lead all Committee meetings. If no chairperson has been appointed or the chairperson of the Committee is absent from any meeting of the Committee, the members of the Committee present at such meeting will select a member of the Committee who is present at the meeting to lead the meeting.

The approval of this Charter by the Board shall be construed as a delegation of authority to the Committeewith respect to the responsibilities set forth herein.

## **RESPONSIBILITIES**

To implement the Committee's purpose, the Committee shall be charged with the following functions and processes with the understanding, however, that the Committee may supplement or (except as otherwise required by applicable laws or rules) deviate from these activities as appropriate under the circumstances:

1. review and advise the Board and management on matters relating to the overall strategy, direction and effectiveness of the Company's R&D strategy and related investments, and on the Company's progress in achieving its long-term strategic R&D goals and objectives;
2. evaluate and monitor, on its own or in conjunction with external experts engaged by the Committee, plans as well as individual project progress and performance of the Company's R&D pipeline;
3. identify and provide the Board with the Committee's views on emerging science and technology issues, innovations and trends that are relevant to the Company and in alignment with the Company's strategy and on areas that are important to the success of the Company's R&D activities;
4. evaluate and advise the Board and management on the opportunities and risks associated with the products, programs and technologies in which the Company is, or is considering, investing its research and development efforts;
5. for any major external investments in R&D that require approval of the Board, assess those opportunities and advise the Board of the Committee's view on the scientific, technical and/or medical merits of the opportunity;
6. assess and advise the Board, from time to time, on the Committee's view of the overall quality and expertise of medical and scientific talent in the Company's R&D organization;
7. assist the Board in understanding the Company's intellectual property position in connection with the foregoing and otherwise;
8. have the authority to delegate any of its responsibilities to individual members of the Committee to the extent deemed appropriate by the Committee in its sole discretion, but subject to the general oversight of the Board;
9. make any recommendations to the Board that the Committee deems appropriate on any areas within its responsibility including where action or improvement is needed; and
10. review and make recommendations on such other related topics as determined by the Board.

## **MEETINGS AND MINUTES**

The Committee will meet whenever its members deem a meeting necessary or appropriate. The Committee will determine where and when to meet. From time to time, or when requested by the Board, the Chairperson of the Committee will report to the Board.

The Committee will maintain written minutes of its meeting and regularly report to the Board on its actions and recommendations. The Committee may act by unanimous written consent; when it does so, those actions will be filed in the minute book.

**COMMITTEE SELF-ASSESSMENT; CHARTER REVIEW**

The Committee will annually evaluate its performance. The Committee shall also review and assess the adequacy of this Charter annually and shall recommend any proposed changes to the Board for its consideration.

**Approved by the Board of Directors: August 10, 2023**

**Effective: August 10, 2023**